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Summary. Animal models of glial-derived neoplasms
are needed to study the biological mechanisms of glioma
tumorigenesis and those that sustain the disease state.
With the aim to develop and characterize a suitable in
vivo experimental mouse model for infiltrating
astrocytoma, with predictable and reproducible growth
patterns that recapitulate human astrocytoma, this study
was undertaken to analyze the long-term course of a
syngeneic orthotopically implanted CT-2A mouse
astrocytoma in C57BL/6J mice. Intracranial injection of
CT-2A cells into caudate-putamen resulted in
development of an aggressive tumor showing typical
features of human glioblastoma multiforme, sharing
close histological, immunohistochemical, proliferative,
and metabolic profiles. To simulate metastatic disease to
the brain, CT-2A cells were injected through the internal
carotid artery. Tumors identical to those obtained by
intracranial injection were obtained. Finally, CT-2A cells
were re-isolated from experimental brain tumors and
transcranially re-injected into the caudate-putamen of
healthy mice. These cells generated new tumors that
were indistinguishable from the initial ones, suggesting
in vivo self-renewal of tumor cells. Small-animal models
are essential for testing novel biological therapies
directed against relevant molecular targets. In a
preliminary study, experimental CT-2A tumors were
chronically treated with the small molecule 77427, a
gastrin-releasing peptide (GRP) blocker compound that
inhibits angiogenesis. Treated animals developed
significantly smaller tumors than controls, suggesting an
antitumor action for 77427 in glioblastomas. We
conclude that the orthotopic CT-2A tumor model, as
described herein, is appropriate to explore the
mechanisms of glioma development and for preclinical
trials of promising drugs. 
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Introduction 
Infiltrating gliomas (astrocytomas, glioblastomas,
mixed gliomas, and oligodendrogliomas) represent the
most common type of primary brain tumor (DeAngelis,
2001; Deorah et al., 2006), with an incidence rate of 5.9
per 100,000 persons-years in the United States according
to the Central Brain Tumor Registry of the United States
(www.cbtrus.org). Approximately 18,000 people in the
United States are diagnosed annually with primary
malignant brain tumors and approximately 13,000
people die from this disease annually (CBTRUS, 2005).
Even though primary brain tumors are rare, accounting
for merely 2-5% of all malignancies, they are, after
stroke, a frequent cause of death from neurological
disorders due to their remarkable resistance to available
treatments. Neoplasms of the central nervous system
(CNS) are, after leukaemia, the second cause of death
due to cancer in children (Kaiser, 1999; McKinley et al.,
2000). The highly infiltrative growth of malignant brain
tumors and difficulties for drug penetration through the
blood-brain barrier and the neural parenchyma determine
a limited number of therapeutic options. Hence, there is
a crucial need for new and better therapeutic strategies
for brain tumors. The development of specific anti-
cancer treatments requires a good understanding of the
initiation and progression process of gliomas. Recently,
specific brain tumor stem cells, named glioma stem
cells, have been identified (Vescovi et al., 2006),
although there is still discussion on whether these cells
cause glioma initiation and progression or are the result
of such processes (Fan et al., 2006). 
Among the primary tumors found in the CNS,
astrocytic neoplasms are by far the most common type.
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Despite tremendous technical improvements in
neuroimaging and neurosurgery, the morbidity and
mortality caused by this malignancy is highly significant
and the incidence of brain cancer is increasing in both
children and the elderly (McKinley et al., 2000). Human
astrocytomas are well-differentiated tumors that grow
slowly and display an intrinsic tendency for diffuse
infiltration of the neighboring brain structures. They
habitually recur and naturally progress, according to the
classification of the World Health Organization (WHO),
from a lower-grade (WHO grade I), passing through a
medium grade (WHO grade II) to a high-grade
malignancy known as anaplastic astrocytoma (WHO
grade III). The highest grade, glioblastoma multiforme
(GBM) is the most malignant infiltrative astrocytoma
and one of the most lethal of all cancers (WHO grade
IV) (Kleihues and Ohgaki, 1997; Kleihues et al., 2002).
Progression through this scale is responsible for the
majority of patient mortality, providing also the rationale
for early detection. 
Understanding the tumor–host interactions
represents an attractive objective for cancer therapy. In
the CNS, tumors elicit a response from their host which
includes, among others, angiogenesis. Angiogenesis is a
complex physiological process involving a number of
tightly controlled sequential events that occurs under
normal and pathological conditions (Kaur et al., 2004).
Tumor angiogenesis is a major independent prognostic
factor since it is a key process in tumor growth and
metastasis (Folkman, 1971; Jung et al., 2006; Kalluri
and Zeisberg, 2006). Since all solid tumors are
neovascularized by the time they are detected and in the
absence of an adequate vasculature, tumor cells become
necrotic and/or apoptotic (Holmgren et al., 1995),
understanding the regulation of tumor angiogenesis has
become one of the most exciting new developments in
anticancer therapy (Gasparini et al., 2005).
Microvascular proliferation is a key feature in glioma
grading, separating low-grade primary tumors from
malignant gliomas depending on the number of vessels
per microscopic field (Wesseling et al., 1998). A number
of angiogenesis inhibition strategies have been proposed
as anticancer therapies (Brown and Wilson, 2004;
Gasparini et al., 2005). In physiological states,
angiogenesis depends on a strictly regulated equilibrium
between stimulatory and inhibitory angiogenic factors
(Folkman, 1992). In neoplasia, the angiogenic balance is
tipped in favor of new vessel growth (Hanahan and
Folkman, 1996). The onset of angiogenesis in cancer is
under investigation and appears to involve down-
regulation of endogenous angiogenesis inhibitors and the
implication of intracellular pathways required for
embryonic vascular development (Patel et al., 2005).
Gliomas are particularly well vascularized and,
therefore, serve as a model to study the process of tumor
angiogenesis and to investigate anti-angiogenic
therapies. Tumor angiogenesis results in vessels with
severe malformations. The morphology of the new
tumor vessels is dilated, tortuous, elongated, and
chaotically organized. Tumor vessels can be void of
smooth muscle cells and lack normal innervation (Jain,
2003). Unlike the vessels in normal brain tissue, tumor
vessels are highly permeable (Dvorak et al., 1999),
allowing the selective uptake of anticancer drugs (Konno
et al., 1986). 
Identification of reliable models that recapitulate the
cellular and molecular features of specific human
cancers is needed to accelerate both the understanding of
the molecular pathogenesis of cancer and the discovery
of therapeutic targets (Peterson et al., 1994). As
knowledge of the molecular biology of neoplasia has
advanced, transgenic technology has been utilized in
elucidating the complex molecular mechanisms
underlying oncogenesis and progression of brain tumors.
Experimental models for brain tumors that include
genetically modified mice, with overexpressed and/or
deleted genes, have been created (Ding et al., 2001;
Reilly and Jacks, 2001; Hu and Holland, 2005).
However, since there are no adequate mechanisms to
correlate genetic alterations in mouse tumors with their
proposed human counterpart, to what extent the existing
mouse models mimic the biology of brain cancer in
humans remains uncertain. The gene expression profiles,
controlling elements, pathways, and cells of origin for
brain tumors remain largely unknown and the molecular
elements, such as tissue-specific promoters and
enhancers, to create genetically accurate models of brain
tumors are still poorly understood. On the other hand,
established human glioma cell lines experience over
time numerous morphologic and genetic changes and do
not reproduce the biology of the tumor in vivo. This
study aims to better standardise an orthotopic model of
mouse infiltrating astrocytoma that mimics the human
clinical situation in terms of histopathological
characteristics and angiogenic features. 
We have developed a transplant-based model of
mouse astrocytoma derived from cultured CT-2A cells
(Zimmerman and Arnold, 1941; Abate et al., 2006)
which closely replicates the biology of human
astrocytoma more efficiently than do the currently
available immortalized glioma cell lines and other in
vivo models. Characterization of the experimental tumor
was performed using histopathology, immuno-
histochemistry, and non-invasive imaging procedures
(MRI). In conclusion, this tumor model recapitulates
well the human astrocytoma disease and can be used for
preclinical testing.
Material and methods
Cell culture
CT-2A mouse astrocytoma cells (Abate et al., 2006)
were obtained as a generous gift from Prof. T.N.
Seyfried (Boston, MA, USA). Tumor cells were grown
in RPMI 1640 medium (Gibco, Invitrogen Co.,
Carlsbad, CA, USA) supplemented with 10% heat-
inactivated fetal bovine serum (R10) in a humidified
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atmosphere containing 95% air and 5% CO2 at 37°C.
Upon reaching confluency, the cells were trypsinized
and collected. The pellet was resuspended in RPMI 1640
medium and the cell suspension was adjusted to obtain
an appropriate concentration of cells for injection (8x104
cells in 4 µl). 
Mouse model
A total of forty one adult 12-week-old C57BL/6J,
four BALB/c, and four SJL female mice (Harlan Iberica,
Barcelona, Spain) weighing 20-25 g were used in this
study. All procedures were carried out in accordance
with the European Communities Council Directive
(86/609/EEE) on animal experiments and with the
Ethical Committee of the Spanish Council for Scientific
Research (CSIC). 
CT-2A cells were injected into the right caudate-
putamen (CP) of twenty six experimental animals by
intracranial injection using stereotaxic guidance. Mice
were deeply anesthetized with pentobarbital (10 mg/kg)
and atropine (90 mg/kg) intraperitoneally and placed in a
mouse stereotaxic frame (David Kopf Instruments,
Tujunga, CA, USA). While under deep anesthesia, a
sagittal incision was made through the skin to expose the
skull, and a burr hole was drilled at 0.1 mm anterior and
2.25 mm lateral to bregma. A 10 µl Hamilton syringe
(Hamilton, Reno, NV, USA) with a 27-gauge needle was
inserted at the depth of 2.7 mm from brain surface for
infusion of tumor cells. The tumor cells were injected
over 15 min. at a speed of 1 µl/3 min. The burr hole was
then filled with spongostan (Ferrosan A/S, Soeborg,
Denmark) and the scalp sutured. Tumor growth and
progression were examined by in vivo MRI and
histopathology at 7, 14, 21, and 28 days following cell
injection. A total of four animals received an intracranial
injection of 4 µl of RPMI 1640 medium in the CP. These
animals, used as controls, were processed in parallel
with those receiving CT-2A cells.
Alternatively, CT-2A tumor cells re-isolated from an
in vivo experimental CT-2A brain tumor, were injected
again in the CP of two healthy anesthetized mice. For
this, the experimental CT-2A tumor was excised from
the brain, washed with minimal essential medium
containing 1% penicillin and streptomycin (Gibco),
minced and triturated with a Pasteur pipette while in R10
medium, and plated into plastic culture flasks. At
confluency, the cultures were trypsinized, and the pellet
resuspended in RPMI 1640 medium. The cell suspension
was adjusted to obtain an appropriate concentration of
cells for injection (8x104 cells in 4 µl). 
CT-2A cells were also injected in the carotid artery,
to simulate metastatic invasion. For this, following
alcohol disinfection, the skin of the neck of four
C57BL/6J mice was cut by a medial incision, and the
common right side carotid artery was exposed. Three
ligatures of 7-0 silk suture were placed, i) around the
origin of the common carotid artery, ii) proximal to the
carotidal bifurcation, which was not closed immediately,
and iii) around the origin of the external carotid. A
polyethylene tube (PE 10, BD, Franklin Lakes, NJ,
USA) containing the tumor cell suspension (8x104 cells
in 10 µl) and connected to a 50 µl Hamilton syringe was
inserted into the common carotid artery and placed in the
origin of the internal carotid artery. At this point, the
second ligature was tightened around the polyethylene
tube to avoid leakage. After tube insertion, a volume of
10 µl containing the cell suspension was slowly injected.
The external carotid artery was kept permanently
closed to prevent tumor cell reflux into the external
carotid and subsequent local tumor cell spread. Then, the
tube was removed and the second ligature was closed
permanently. 
To investigate the influence of the immune system in
tumor progression, CT-2A cells were injected in four
BALBc and four SJL mice. No tumors developed in
these mice.
Magnetic resonance imaging
Mouse tumor growth was imaged weekly by MRI,
starting 7 days after tumor cell injection, at 4.7 Teslas
using a BIOSPEC BMT 47/40 (Bruker, Ettlingen,
Germany), equipped with a 12 cm actively shielded
gradient system. Mice were anaesthetized as above and
injected intraperitoneally with 0.4 mmol/kg
Gadopentetate dimeglumine (Gadolinium, Magnevist,
Schering, Germany). Mice were put in prone position
inside a cradle to avoid unexpected movements. A
respiration sensor was used to survey the animals vital
functions. First we acquired T2 weighted images using a
fast spin echo sequence. The acquisition parameters
were: TR = 4000 ms, effective TE = 60 ms, FOV = 3
cm, Slice Thickness = 1 mm and matrix = 256x192. This
matrix size was increased during reconstruction by a
zero-filling process in order to obtain images of 256x256
pixels. After that, we acquired T1 (TR/TE=700/15 ms)
weighted spin echo images using the same geometrical
parameters as above. These images were used to
calculate tumor volume using ParaVision software
(Bruker, Ettlingen, Germany). 
HR-MAS 1H NMR data acquisition 
The spectroscopy procedures followed in this study
have been previously described (Cheng et al., 1998).
Briefly, tissue specimens taken from CT-2A tumor and
the contralateral healthy region were snap-frozen in
liquid nitrogen and maintained at -80°C until
spectroscopic analysis. Cerebral tissue was examined
using high resolution magic angle spinning (HR-MAS)
operating at 4°C to minimize tissue degradation, 1H-
NMR spectroscopy was performed at 500.13 MHz using
a Bruker AMX500 spectrometer 11.7 T. Samples were
obtained from histologically defined coronal slides of
brains four weeks after CT-2A implants and were placed
within a 12 ml zirconium oxide rotor with spherical
insert and spun at 4000 Hz spinning rate, to remove the
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effects of spinning side bands from the spectra acquired.
Shimming and NMR preparation time was kept to a
minimum and the NMR analysis was performed at 4°C
to minimize metabolic changes. Under such conditions
no noticeable biochemical degradation of the samples
was observed during spectral acquisition. Standard
solvent suppressed spectra were acquired in 16 k data
points, averaged over 128 acquisitions, total acquisition
~5 min using a sequence based on the first increment of
the NOESY pulse sequence to effect suppression of the
water resonance and limit the effect of Bo and B1 in
homogeneities in the spectra (relaxation delay-90°-t1-90°-tm-90°- acquire free induction decay (FID)) in which
a secondary radio frequency irradiation field is applied at
the water resonance frequency during the relaxation
delay of 1s and during the mixing period (tm = 150ms),
with t1 fixed at 3 s. A spectral width of 8333.33 Hz was
used. All spectra were processed using TOPSPIN
software, version 1.3 (Bruker Rheinstetten, Germany).
Prior to Fourier transformation, the FIDs were multiplied
by an exponential weight function corresponding to a
line broadening of 0.3 Hz. Spectra were phased,
baseline-corrected and referenced to the sodium TSP [(3-
trimethylsilyl)-2,2,3,3-tetradeuteriopropionate] singlet at
δ 0ppm. 1H NMR spectra were data reduced using the
software program AMIX (Analysis of MIXtures version
3.6.8, Bruker Rheinstetten, Germany) by subdivision
into integral regions of 0.02 ppm between δ 0.4 and 4.6
ppm. Individual integral regions were normalized to the
total integral region following exclusion of the water
resonance. Principal component analysis (PCA) was
applied to the data and used no scaling by weighting
each integral region or variable by 1/√Sk where Sk
represents the standard deviation of the variable. The
analysis increased the representation of lower
concentration metabolites in the resultant data models
while minimizing noise. Loading plots from the PCA
were used to identify metabolites.
Histopathology 
All mice were clinically evaluated and sacrificed at
different time intervals, 7, 14, 21, and 28 days following
cell implants. Experimental animals were sacrificed if
they showed signs of motor disfunction or exhibited
symptoms consistent with failure to thrive as per animal
care protocols. Histopathology was performed on
coronal tissue sections obtained through the same rostro-
caudal levels that were previously identified by MRI as
exhibiting tumor growth. Mice were deeply anesthetized
as for MRI and then perfused transcardially through a
blunt cannula with 20 ml phosphate-buffered saline
(PBS) followed by 40 ml of 4% paraformaldehyde in 0.1
M phosphate buffer (PB), pH 7.4. Brains were then
removed and post-fixed for 4 hours by immersion in the
same fixative, at room temperature. For H&E stain tissue
blocks were paraffin embedded and then cut coronally in
5-µm sections. For light microscopy immuno-
histochemistry, brain tissue was sectioned at 40-µm in
the coronal plane with the aid of a vibratome (Leica
Microsystems GmbH, Wetzlar, Germany). 
Immunohistochemistry
The expression of the p53 tumor suppressor protein
(p53) in the experimental tumor was evaluated using a
mouse monoclonal antibody (EXBIO, Praha, Czech
Republic). The glial origin of the CT-2A cells was
indicated by the presence of GFAP by using a mouse
monoclonal antibody (GFAP, Sigma CO, St. Louis, MO,
USA). The presence of Sox family of transcription
factors 9 and 10 in tumor cells was screened by using
polyclonal antibodies which have been previously
characterized (Maka et al., 2005; Stolt et al., 2003) and
were a generous gift from Dr. Michael Wegner (Institut
fur Biochimie, Universitat Erlangen-Nuremberg,
Germany). Polyclonal antibodies against NOS isoforms
(neuronal: nNOS, endothelial: eNOS, and inducible:
iNOS) and nitrotyrosine, a marker of final protein
nitration (Encinas et al., 2003), were used to follow the
expression of the nitrergic system as the experimental
CT-2A tumor grew. Antisera against nNOS, iNOS and
nitrotyrosine were produced in house as previously
described (Rodrigo et al., 1994). eNOS immuno-
cytochemistry was performed with a polyclonal antibody
(Transduction Laboratories, Lexington, KY, USA).
Adrenomedullin (AM) expression in CT-2A
experimental tumor was carried out by using polyclonal
antibodies that were also produced in house (Martinez et
al., 1995). 
Immunohistochemistry was performed according to
standard avidin-biotin-peroxidase complex (ABC)
methods (Hsu et al., 1981). Immunohistochemistry with
p53 was performed on paraffin-embedded tissue sections
(5 µm-thick). For this, tissue sections were pretreated for
antigen retrieval at high temperature (microwave) in 10
mM citrate buffer pH 6.0 for 5 min. Immuno-
histochemistry for GFAP, Sox transcription factors 9 and
10, NOS isoforms, nitrotyrosine, and AM was carried
out in free-floating sections that were preincubated in
1% H2O2 in PBS for one hour to block endogenous
peroxidase. Sections were then treated with 3% normal
serum obtained from the species providing the secondary
antibodies diluted in PBS containing 0.2% Triton X-100,
for 1 h at room temperature (RT). Then, sections were
incubated overnight at 4°C in the primary antibodies
diluted in PBS containing 0.2% Triton X-100.
Antibodies dilutions were: i) p53, 1:100, ii) GFAP,
1:500; iii) Sox9, 1:2000, iv) Sox10,1:500, v) nNOS,
1:3000), vi) iNOS, 1:5000, vii) eNOS, 1:1000, viii)
nitrotyrosine, 1:1000, and ix) AM, 1:1000. After
washing thoroughly in PBS, histological sections were
incubated with biotinylated secondary antibodies, goat
anti-mouse or goat anti-rabbit immunoglobulins 1:200 in
PBS (Vector Laboratories, Burlingame, CA, USA), for 1
h at RT. After additional washes, sections were
incubated with peroxidase-linked ABC (Vector
Laboratories) for 90 min. Peroxidase activity was
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developed by nickel enhanced 3,3’-diaminobenzidine
tetrahydrochloride (DAB) as described (Rodrigo et al.,
1994). Finally, sections were washed, mounted and
dehydrated for light microscopy visualization.
Histological sections were examined with a Zeiss
Axiophot II microscope (Zeiss Iberica, Madrid, Spain)
and images captured with a digital camera (DMC le,
Polaroid, Cambridge, MA, USA). Immunofluorescence
staining for confocal microscopy was carried out by
incubating tissue sections in the specific antibodies for
GFAP and Sox9 diluted as for ABC procedure. Sections
were then thoroughly washed and incubated with Cy3-
donkey anti-mouse IgG and Rhodamine Red donkey
anti-rabbit IgG (Jackson ImmunoResearch, West Grove
PA, USA) diluted 1:200 in PBS, for 1 hour at RT.
Confocal images were acquired using a Leica TCS SP5
(Leica Microsystems GmbH, Wetzlar, Germany)
scanner. 
Ultrastructural studies of experimental CT-2A tumor
were carried out in 40-µm-thick tissue sections. Before
cutting, tissue blocks were rapidly frozen in liquid
nitrogen and thawed in cold 0.1M PB to improve
antibody penetration. For the subcellular location of
AM, tissue sections were processed as for light
microscopy, except that Triton X-100 was avoided in the
incubation steps. The immunocytochemical reaction was
developed by incubating the tissue sections in PBS
containing 0.006% DAB, for 10 min followed by
0.003% of H2O2 in the same solution. Subsequently, the
sections were washed for 5 min in PBS and PB,
postfixed in 1% osmium tetroxide in 0.1M PB for 1
hour, dehydrated in ethanol of increasing concentrations
and block-stained in uranyl acetate (1% in 70% ethanol)
in the dark for 40 min at room temperature. The sections
were then flat embedded and mounted on Durcupan
ACM resin slides (Sigma-Aldrich Inc.) under plastic
coverslips and cured for 3 days at 56°C. Selected areas
of the immunostained tumor were dissected out and re-
embedded in Durcupan. Ultrathin sections were obtained
with the aid of a Reichert OM U3 ultramicrotome
(Reichert, Germany), mounted on formwar-coated grids,
stained with lead citrate, and examined under a Jeol
1200 electron microscope (Jeol, Tokyo, Japan) at 80 Kv.
No immunolabeling was detected when the primary
antibodies were omitted or replaced with an equivalent
concentration of normal mouse or rabbit serum. In
addition, preabsorption with an excess of the antigen
prevented staining in all cases. 
Results
Tumor growth
CT-2A cells grew in vitro as a monolayer of fusiform
shaped cells. Three to four weeks following cell implant,
a highly angiogenic and haemorrhagic soft tumor (Fig.
1A) was detected in treated mice, obtaining a 100%
tumorigenesis rate. The tumor margins were typically
well defined (Fig. 1B-E), merging discernibly with the
adjacent white and gray matter (Figs 1E). Five to ten
days following intracranial injection with CT-2A cells, a
soft, non cohesive hypercellular mass was observed near
the injection site (Fig. 1F). Histological analysis showed
characteristic features of a high-grade astrocytoma, such
as high mitotic index, microvascular proliferation,
cellular density and a central area of necrosis
(pseudopalisading necrosis) (Figs 1G,H, 2, 3A). The
tumors showed extensive heterogeneity (Fig. 1H). A
subset of tumor cells infiltrated into the surrounding
brain tissue following tracks marked by blood vessels
(Fig. 2). 
Tumor CT-2A cells harvested from transplanted
animals and grown in tissue culture formed a monolayer
of fusiform cells. Almost all the cells retrieved from the
tumor had morphological characteristics of tumor cells
with very little contamination from stromal components,
possibly due to the well defined margins of the tumor.
These re-cultured tumor cells maintained high
proliferating capacity when re-implanted transcranially
into healthy mice. In addition, injection of CT-2A cells
into the carotid artery caused a metastatic tumor growth
in the homolateral hemisphere 7-10 days following cell
inoculation in all animals treated. The resulting tumors
had the same growing characteristics and histological
features as those generated following intracranial CT-2A
cell injection (data not shown). 
Under the electron microscope, tumor cells were
pleomorphic, either large fusiform or small, with
characteristic nuclei which exhibited areas of
heterochromatin and frequent prominent nucleoli (Fig.
3). The cytoplasm contained abundant mitochondria and
polyribosomes, indicating a high metabolic and synthetic
rate. 
RMI analysis
Conventional T2- and T1- weighted (pre- and
Gadolinium post-contrast) MRI images provided
exceptional sensitivity in detecting and delineating the
location of intracranial tumors (Figs 1B-D, 4). The
recognition of intracranial tumors was markedly
enhanced with prior administration of Gadolinium (Figs
1B-D; 4A,C,E), with a resolution limit of 0.013 mm2.
T1-weighted imaging with Gadolinium enhancement of
vascularity was routinely used to detect tumor location,
margins, size, and growth. The MRI images regarding
tumor size and location correlated accurately with the
results of the histopathological analysis in this study
(compare Fig. 1D with Fig. 1E). T1-weighed images
revealed a well-defined heterogeneously enhancing mass
that arose in the CP (Fig. 1B), extending over time
rostro-caudally and eventually involving the cerebral
cortex and hippocampus (Figs. 1C,D, 4A,C,E).
Occasionally, the tumor grew outside of the skull
through the needle tract (Fig. 1C). Tumor progression
was verified by serial MRI over time and weekly images
of experimental CT-2A tumors were successfully
obtained (Fig. 4). The experimental tumor was
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characterized by rapid growth being already apparent at
1 week post-injection (Figs. 1B, 4A) and becoming too
large at 4 weeks (Figs 1C,D, 4E,F). At that time mice
began to present neurological complications and had to
be sacrificed for welfare reasons.
Tumor growth resulted in marked deformation of the
1314
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Fig. 1. Characterization of CT-2A induced brain tumors. A. Mouse brain with haemorrhagic CT-2A tumor mass lying in the right cerebral hemisphere,
28 days following CT-2A cell injection. The photograph was taken after in vivo MRI (B-D) and removal of the brain at the time of necropsy for histology
(E, G, H). B-D. T1–weighted (Gadolinium postcontrast) images corresponding to the same experimental CT-2A tumor depicted in A, showing the tumor
progression over time, (B) one week and (C, D) four weeks following cell implant. Notice that in B the hyperintense signal is restricted to the CP on the
right hemisphere. C and D. Serial coronal MRI images at different distances from the olfactory bulb. The rapid growth of the tumor can be visualized
comparing B with C and D. Notice that necrosis in D appears as an area of decreased T1 signal (arrow). Also, notice in D hyperintense signal in the
rim of the tumor indicating that the tumor border is well-vascularized. F. Histopathologic section through a tumor mass ten days after intracranial CT-2A
cell injection. H&E staining revealed high density of irregularly shaped cells. G, H. Histopathologic sections of the tumor shown in B-E exhibiting the
features of GBM following H&E staining, including (G) nuclear pleomorfism and numerous mitotic figures and (H), pseudopalidasing, intratumoral
hemorrhage and necrosis. Scale bars: A, G, 10 µm; B-E, 5 mm; F, 1.25 mm; H, 20 µm.
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Fig. 2. A. Light micrograph of a H&E stained section illustrating CT-2A cells located close to the rim of the tumor and infiltrating the surrounding
neuropil following host vasculature (asterisk) caming from the neighbouring cerebral cortex. B. High-power magnification of the boxed area in A. Mitotic
figures near a pre-existing blood vessel are detected. Scale bars: A, 100 µm; B 10 µm.
Fig. 3. A. Light
micoscopic image of
osmium-stained
normal brain tissue
(dark) and adjacent
CT-2A tumor (light
color). Numerous
intratumoral blood
vessels (asterisks)
are seen in the
tumor. B. Electron
micrograph showing
the fine morphology
of the neuropil in
normal brain tissue
far from tumor
growth. C and D.
Electron micrographs
illustrating the
ultrastructural
appearance of tumor
cells in the transition
zone (C) and deep in
the tumor (D). Tumor
cells show cytological
pleomorphism with
prominent nucleoli,
slender processes
and characteristic
heterochromatin.
Scale bars: A, 100
µm; B-D, 2.5 µm.
lateral and dorsal third ventricles (Fig. 4D,F). A central
hypo-attenuation of the tumor was frequently seen in T1-
weighted images suggesting central necrosis (Fig. 1D)
which was confirmed in the histological analysis of
those cases (Fig. 1G,H). In addition, cystic changes
within the tumor were occasionally detected in T2-
weighted images (Fig. 4F).Tumor growth provoked
signs of destruction of brain parenchyma and of
increasing pressure within the brain as it invaded the
neighboring brain structures (Figs 1A-E,G,H; 4). After
15-20 days post implantation, mice began to show signs
of raised intracranial pressure. Symptoms such as
lethargy or motor disfunctions with hunched posture,
poor grooming, failure to thrive and weight loss, were
common. The periphery of the tumor had in all instances
a well-established blood supply as revealed by the
enhanced pattern in T1-weighted images with
Gadolinium (Fig. 4E).
Immunohistochemistry
Immunostaining for p53 was exclusively nuclear and
was exhibited by numerous cells in the tumor mass (Fig.
5A). GFAP immunoreactivity was detected in normal
astrocytes of the brain parenchyma outside the tumor
and also in tumor cells (Fig. 5B-E). The reaction product
1316
Brain tumor model
Fig. 4. MRI coronal images
performed at different time
intervals showing progressive
tumor growth in an
experimental animal after
intracranial injection of CT-2A
astrocytoma cells.
Assessment of tumor volume
changes is shown by using
Gadolinium enhanced T1- (A,
C, E) and T2- (B, D, F)
weighted images. A,B,
Sections at the same level
one week post injection. A
small tumor mass in A (arrow)
is located deep in the CP. At
this time point, T2-weighted
image (B) is unable to detect
the tumor mass shown in A. 
C, D. Aspect of the tumor two
weeks post-injection. At this
time point, the tumor mass
(arrow in D) displaces the
lateral ventricle allowing tumor
identification by T2-weighted
image. E, F. Enlarged tumor
four weeks post-injection.
Thin rim of contrast
enhancement is seen around
the tumor as well as a nodular
enhancement inside the tumor
(E). With T2 a mass effect
distorting the right lateral and
dorsal ventricles and a small
enhancing hyperintense area
(arrow) likely representing a
cyst are clearly seen (F).
Scale bar: 5 µm.
accumulated diffusely in the cytoplasm of tumor cells,
and GFAP-positive cells were more frequent in the
tumor edge (Fig. 5E). GFAP immunostaining also
delineated the wall of small vessels within the tumor
(Fig. 5C). Characteristically, astrocytes showing normal
features (Fig. 5D) were not detected inside the tumor
where only tumor cells were positive for GFAP (Fig.
5E). 
Sox9 and Sox10 immunocytochemical expressions
presented different patterns in experimental CT-2A
tumors. Tumor cells displaying strong nuclear staining
for either Sox9 or Sox10 were detected in the tumor cells
and in normal astrocytes (Fig. 6). Numerous Sox9
positive cells were detected within the tumor mass,
being more abundant near blood vessels and in the tumor
rim (Fig. 6A,B). Immunoreactive Sox10 cells in the rim
of the tumor were also abundant (Fig. 6C,D). In contrast,
Sox10 immunoreactive cells were very infrequent inside
the tumor mass. Double immunofluorescence revealed
that Sox9- and GFAP-positive CT-2A cells formed
distinct subpopulations (Fig. 6E). CT-2A cells exhibiting
both Sox9- and GFAP-positive staining were numerous,
but cells staining for only one of the antibodies were also
located (Fig. 6E). As expected, astrocytes in the
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Fig. 5. A. Immunocytochemical staining of p53 in a CT-2A tumor mass showing nuclear staining. B-E. GFAP-positive structures in and around the
experimental tumor as revealed by immunohistochemistry (B, C) and immunofluorescence (D, E) staining procedures. B. Distribution of the
immunoreaction product in both normal brain tissue (right hand side) and the CT-2A tumor (left hand side). Inset in A is a high-power magnification
photograph showing two immunoreactive astrocytes in the normal neuropil surrounding the tumor. C. High-power magnification of the tumor area
showing the elevated cell density of GFAP-positive tumor cells (some pointed by arrows) and the presence of immunostaining (thick arrow) in the wall
of a capillary (asterisk). D, E. GFAP-positivity in astrocytes near tumor mass (D) and in CT-2A cells (E). Scale bars: A: 10 µm; B, 100 µm; C-E, inset in
B, 20 µm.
neocortex exhibited double labelling for GFAP and Sox9
(Fig. 6F). Remarkably, we also observed Sox9 positive
staining in Golgi-like structures of GFAP-negative cells,
probably belonging to cortical neurons (arrows in Fig.
6F). 
With regard to the immunocytochemical location of
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Fig. 6. Distribution of Sox9 (A, B, E, F) and Sox10 (C, D) in and around the experimental tumor. A. High cellular density of Sox9 stained cells was seen
near blood vessels (asterisk) and in the rim of the tumor. B. is a higher-power magnification micrograph of stained structures shown in A. C. Sox10-
positive cells accumulated in the rim of the tumor. D. Details of immunoreactive cells displayed in C. Both immunoreactivities were located in the cell
nuclei (E, D). Note in A and C the rich vasculature (asterisks) in the rim of the tumor. E, F. Double immunofluorescence staining of a section through
the tumor mass (E) and the cerebral cortex (F) double labelled for GFAP (green) and Sox9 (red). Most tumor cells stained for both GFAP and Sox9,
although a few cells expressed GFAP and not Sox9 (arrowheads) or viceversa (arrow). In normal brain (F), astrocytes express both. Surprisingly, Sox9
staining was also found in structures suggesting Golgi apparatus cisternae of neighboring GFAP-negative cells (some pointed by arrows). Scale bars:
A, C, E, 100 µm; B, 20 µm; D, F, G, 10 µm; H, 30 µm.
the nitrergic system, we found that nNOS staining
revealed a complete destruction of the nNOS neuronal
network within the tumor (Fig. 7A). Positive nNOS
neurons exhibiting varicose processes suggesting
advanced neurodegeneration were often detected in the
margins of the tumor (Fig. 7A,B), whereas no nNOS
immunoreactive cell was seen further inside the tumor.
In the neuropil outside the tumor, nNOS
immunoreaction product marked neurons showing
normal morphologies (Fig. 7A,C). The complete
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Fig. 7.
Immunocytochemical
localization of nNOS
(A-C), iNOS (D),
eNOS (E),
nitrotyrosine (F) and
AM (G, H) in the
experimental CT-2A
tumor. Left-hand side
in A and B, nNOS-
positive neurons in
the tumor mass
exhibiting abnormal
features. Notice in A
and B that
immunoreactive
neurons in the tumor
mass display
varicose processes
suggesting
degeneration. In
contrast, an nNOS
immunoreactive
neuron showing
typical morphology
can be appreciated in
the CP (arrow) near
the tumor mass (A).
C. nNOS-positive
neurons in the side
contralateral to the
tumor displaying
typical morphology. A
number of tumor cells
(some pointed by
arrows) are seen
exhibiting
immunostaining for
iNOS particularly in
the rim of the tumor
(D), eNOS (E),
nitrotyrosine (F) and
AM (G). E. Depicts
immunoreaction
product associated to
the wall of small
capillaries (asterisks).
H. Illustrates intense
immunostaining in
tumor cells
characteristically
showing cytological
pleomorphism by
electron microscopy.
Scale bars: A-C, 20
µm; D-G, 10 µm; H, 2
µm. 
degeneration of the neuronal network was also seen by
electron microscopy (Fig. 3). In contrast, iNOS, eNOS,
and nitrotyrosine immunoreactivities were stronger in
tumor structures than in the surrounding brain tissue
(Fig.7D-F). iNOS, eNOS, and nitrotyrosine
immunoreactivities typically labeled the cytoplasm of a
subset of tumor cells (Fig. 7D,E,F). In addition, eNOS
staining was very intense in the wall of blood vessels
(Fig. 7E). Outside the tumor, eNOS was detected in
endothelia of blood vessels and occasional astrocyte-like
cells, but never in neurons (data not shown). No
immunoreactivity for either iNOS or nitrotyrosine was
seen in the non-affected neuropil.
Concerning AM immunoreactivity, light and
electron microscopic studies revealed deposition of the
reaction product in the cell nucleus and/or cytoplasm of
a subpopulation of tumor cells (Fig. 7G,H). Through the
electron microscope, these cells show the
immunoreaction product associated with the external
surface of cytoplasmatic organelles and the cell nucleus
and the inner surface of the cytoplasmatic membrane
(Fig. 7H). AM immunoreactive cells lie in the proximity
of non-immunoreactive tumor cells showing similar
morphological traits. Positive and negative tumor cells
were pleomorphic, with either large fusiform or small
rounded morphology. 
HR-MAS 1H NMR
A direct comparison between the ex vivo HR-MAS
1H NMR spectra of the CT-2A tumor and normal brain
in the contralateral side of the tumor, was carried out
using both comparison of metabolite ratios and/or
pattern recognition methods (Fig. 8). Spectra were
composed of resonances deriving, among others, from
lactate (Lac), alanine (Ala), γ-aminobutyric acid
(GABA), acetate (Ace), glutamate (Glu), aspartate
(Asp), creatine (Cr), choline (Cho), phosphorylcholine
(PCh), taurine (Tau), N-acetylaspartate (NAA) myo-
inositol (Myo), and glycine (Gly). Following the same
criteria used by Tsang et al. (2005) we found no
significant biochemical degradation of the samples
during spectral acquisition. The spectrum of the CT-2A
tumor, compared with the normal contralateral brain,
revealed an increased signal for Cho (at 3.20 ppm), and
PCh (at 3.22 ppm). There were also higher signals in the
tumor related with Lac (at 1.3 ppm), Ala (at 1.48 ppm),
Tau (at 3.26 ppm and 3.42 ppm), Gly (at 3.56 ppm),
Myo (at 3.53) and Glu (at 3.79 ppm). On the other hand,
the tumor showed lower signals for NAA (at 2.02 ppm),
GABA (at 1.83 ppm and 2.22 ppm), Asp (at 2.68-2.82
ppm), and Cr (at 3.04 ppm). 
Discussion
We have standardized an orthotopic mouse model of
malignant mouse astrocytoma, CT-2A, in terms of
histopathological characteristics and angiogenic features.
The animal model has been produced after an
intracerebral injection of CT-2A cells (Seyfried et al.,
1992) into the CP. The resulting CT-2A tumor model
exhibited common features with the human astrocytoma
disease, as shown by histopathology, immunohisto-
chemistry, and non-invasive imaging procedures (MRI).
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Fig. 8. High-resolution 1H-NMR spectra of
aqueous extracts of CT-2A tumor (A) and of
the normal contralateral area (B). Selected
metabolite resonances are labelled on
spectrum. Abbreviations in the f igure
correspond to: Ala: alanine; Asp: aspartate;
Cho: choline; Cr: creatine; GABA: γ -
aminobutyric acid; Glu: glutamate; Gly: glycine;
Lac: lactate; Myo: myoinositol; NAA: N-
acetylaspartate; PCh: phosphorylcholine; PCr:
phosphocreatine; Tau: taurine
Given that tumor-host interactions are organ specific,
mouse models should be orthotopic to better reproduce
their biology. It is also important to take into account the
contribution of the immune system. For this reason our
model was developed using immunocompetent
syngeneic mice. 
CT-2A tumor cells were produced in the Seyfried
laboratory by implantation of a chemical carcinogen, 20-
methylcholanthrene, into the cerebral cortex of
C57BL/6J mice, following previous descriptions
(Zimmerman and Arnold, 1941). By implanting CT-2A
tumor pieces (about 1 mm3) from donor mice into the
cerebral cortex of C57BL/6J mice, a syngeneic mouse
brain tumor model was produced (Seyfried et al., 1992;
Abate et al., 2006). Our procedure initiating tumors from
cultured CT-2A cells instead of from solid tumors
improved the method by using a determined number of
cells to initiate the tumor, providing a more quantitative
approach when studying the effect of various treatments
on tumor growth. Additionally, we kept brain damage to
a minimum due to tumor implantation by injecting a
liquid cell suspension rather than tissue fragments.
Intracranial xenograft mouse models using tumor cell
lines or primary cultures have been reported previously
in immunodeficient mice (Bock et al., 2003; Singh et al.,
2004). 
The injection of the CT-2A cells into the CP
produced an aggressive astrocytic neoplasm
histopathologically characterized by pleomorphic,
hyperproliferative, and infiltrative cells. Our observation
that the CT-2A experimental tumor exhibits the
characteristics of a poorly differentiated malignant
astrocytoma is consistent with previous reports (Seyfried
et al., 1992; Mukherjee et al., 2002, 2004). Over time,
tumors became highly cellular with frequent mitosis and
other pathologic characteristics, including vascular
proliferation and areas of necrosis with pseudopalisading
tumor cells, characterizing them as GBM (Yates, 1992;
Fischer et al., 2005; Rong et al., 2006). 
In addition to malignant mouse CT-2A model, other
astrocytoma models have been available both in vitro
and in vivo (Ding et al., 2001; Reilly and Jacks, 2001;
Hu and Holland, 2005; King et al., 2005; Kang et al.,
2006; Khain and Sander, 2006; Lee et al., 2006; Terzis et
al., 2006). However, many of the available models used
to study gliomas in mice and rats do not correctly
reproduce all of the important characteristics of
malignant gliomas in humans, including variability of
phenotypes within individual tumors, the migratory
characteristics in vivo that are such an important feature
of human CNS tumors and the appearance of
radioresistance and chemoresistance. In addition,
established human glioma cell lines develop multiple
genetic changes over time, so that they may no longer
reflect the biology of the tumor in the patient.
Consequently, implantation of these cells in
experimental animals will not reproduce the interaction
between tumor and host that occurs in humans. Tumor
heterogeneity introduces a further difficulty in the
identification of the best-fit mouse models for human
cancers. 
Metastases of tumor cells of various origins to the
brain are frequent (Reilly and Jacks, 2001; Kirsch and
Loeffler, 2004; Becher et al., 2006). To find out whether
CT-2A cells may provide a valid model for brain
metastasis, these cells were injected in the internal
carotid artery and metastatic tumor growths were found
in the brain parenchyma, ipsilateral to the injection site.
This demonstrates also that the progression of the tumor
occurs independently of the lesion caused by the needle
during the injection protocol. Additionally, CT-2A cells
re-isolated from experimental CT-2A tumors, and later
injected into the CP, generated new tumors identical to
the original tumor. Together, these data provide direct
evidence that experimental CT-2A tumors contain
cancerous initiating cells. These cells have potent in vivo
self-renewal and proliferative capacities, generating
tumors that are a phenocopy of the primary experimental
tumor. These facts suggest the existence of tumor stem
cells among the CT-2A cells but a formal identification
of these stem cells should be carried out. In human
GBM, CD133+ cells have been identified and proposed
as potential tumor stem cells (Singh et al., 2004).
Injection of CT-2A cells in mouse strains other than
C57BL/6J did not produce any tumor growth, even 3
months after implantation. CT-2A cells were generated
in C57BL/6J mice (Zimmerman and Arnold, 1941) and,
obviously, are able to escape the immune surveillance in
this strain but not in others. 
To further characterize the phenotype of the CT-2A
induced tumors, detailed immunohistochemical analyses
were performed. Immunohistochemical examination
showed strong positivity for GFAP, the different NOS
isoforms, nitrotyrosine, AM, Sox9, and Sox10. 
The observation of endogenous GFAP in tumor cells
correlates well with previous descriptions that tumor
cells in human astrocytomas express GFAP (Schiffer et
al., 1986; Sembritzki et al., 2002). The morphology of
the GFAP-positive cells inside the tumor is clearly
neoplastic and rather different from normal astrocytes in
the undisturbed parenchyma, indicating that they were
derived from the CT-2A cells and were not trapped
normal astrocytes, which seem to be utterly destroyed by
the tumor as happens with the neurons. 
Both in normal and pathological situations, NO
plays various functions in the CNS including
vasodilatation, neurotransmission, neural plasticity,
neurotoxicity, and oxidative stress (Rodrigo et al., 2005).
Malignant brain neoplasms express high levels of NOS
suggesting that NO production may be associated with
pathophysiological processes essential to these tumors
(Broholm et al., 2003). Although the biological role of
NO in malignancies is still poorly understood, recent
investigations suggest that it may have a dual pro- and
anti-tumor action. While NO can inhibit cell growth and
initiate a free radical injury to normal and tumor cells
leading to apoptosis and necrosis (Tews, 1999), it can
stimulate cell growth, dilate the vessels surrounding the
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tumor thereby ensuring supply, and induce tumor
angiogenesis (Lam-Himlin et al., 2006). It has also been
proposed that NO might stimulate tumor growth and
metastasis by promoting migration, invasion, and
angiogenesis (Pan et al., 2005). NO production in the
endothelium of the intratumoral blood vessels has been
associated with blood flow regulation of the tumor and
as a possible cause of brain edema (Broholm et al.,
2003). Overexpression of eNOS in astrocytoma plays a
crucial role in tumor angiogenesis (Pan et al., 2005).
Taken together, these findings suggest that modulation of
NO production may provide a new therapeutic approach
for brain cancers (Morbidelli et al., 2004; Pan et al.,
2005; Lam-Himlin et al., 2006). 
We found that cancer cells characteristically did not
express nNOS and, in fact, the lack of nNOS
immunoreactivity perfectly demarcated the tumor
boundaries. A small number of nNOS immunoreactive
neurons were detected in the periphery of tumor
surrounded by tumor cells. These cells were swollen and
exhibited processes with abnormal dilatations in their
course, suggesting advanced neurodegeneration. It is
well known that excessive NO generation during stroke,
ischemia, and neurodegenerative diseases contributes to
neuronal cell death (Coyle and Puttfarcken, 1993;
Dawson and Dawson, 1996). In clear contrast,
expression of iNOS was only found in the tumor and not
in the surrounding parenchyma. Our results correlate
with previous findings in humans showing expression of
iNOS immunoreactivity only in proliferative tumor cells
(Kao et al., 2003). We also found a strong staining for
eNOS in both tumor cells and blood vessels, whereas
only a faint immunoreaction was seen in normal vessels
in unaffected areas. This has also been found in human
GBM (Pan et al., 2005). Since progressive tumor growth
is dependent on angiogenesis, the strong expression of
eNOS immunoreactivity within the tumor suggests that
the angiogenic switch has been pushed towards active
angiogenesis promotion. The intense staining for iNOS
and eNOS inside the tumor suggests that excessive NO
may be produced at the tumor site. This is also supported
by the presence of nitrated proteins as shown by
nitrotyrosine immunoreactivity. This excessive
production of NO may be responsible for the destruction
of the brain parenchyma.
AM is a multifunctional regulatory peptide (Lopez
and Martinez, 2002) that operates as a growth factor for
tumor cells, reduces apoptosis, augments tumor cell
motility, and increases angiogenesis (Martinez et al.,
2002). In the CNS, AM is produced by a variety of cells,
including neurons and astrocytes (Serrano et al., 2000).
The expression of AM peptide and its receptor in human
gliomas has been previously reported (Benes et al.,
2004; Mennel et al., 2006). Our identification of a
subpopulation of CT-2A tumor cells exhibiting AM
immunoreactivity correlates well with these previous
findings and supports previous studies that AM may
function as an autocrine growth factor for glioblastoma
cells (Ouafik et al., 2002; Boudouresque et al., 2005).
AM is highly induced in vitro by hypoxia in human
T98G glioblastoma cells (Kitamuro et al., 2000) through
a HIF-1 mediated mechanism (Garayoa et al., 2000). It
has been demonstrated that the use of specific antibodies
against AM consistently reduces the growth of
established glioblastoma xenografts through
angiogenesis supression (Ouafik et al., 2002). Following
this line of research, we have proceeded to evaluate in
vivo the action of the antiangiogenic small molecule
77427 (Martinez et al., 2005; Martinez, 2006) in CT-2A
tumor growth. The results of this experiment are still
very preliminary but they show a reduction of the tumor
volume over time. Since 77427 was applied
systemically, our preliminary results indicate either that
77427 can cross the blood-brain barrier or that the tumor
vasculature allows the extravasation of this small
molecule. In either case, 77427 may constitute a
promising new drug for the treatment of brain cancers.
Sox (Sry-type HMG box) genes constitute a large
family of transcription factors that play critical roles in
gene regulation during embryogenesis (Wegner, 2001).
These proteins belong to the High Mobility Group
(HMG) superfamily, which is well conserved across
species. Neural crest development is regulated by the
transcription factor Sox9 (Cheung and Briscoe, 2003)
which is strongly expressed first in neural stem cells and
then in glial cells of the CNS, which suggests Sox9 as a
component of the mechanism that causes neural stem
cells to switch from neurogenesis to gliogenesis (Stolt et
al., 2003). Levels of HMG protein expression have been
correlated with tumor progression, with malignant cells
expressing high levels and benign tumor cells or normal
cells in adult tissues exhibiting little or no expression of
Sox9 (Wunderlich and Bottger, 1997). It has been
suggested that Sox9 suppresses apoptosis (Akiyama et
al., 2002), and this protein has been proposed as a novel
candidate marker of stem cells (Sottile et al., 2006) and a
potential genetic marker for cancer (Dong et al., 2004).
In the CNS, Sox10 transcripts were originally thought to
be confined to glial precursors but later were detected in
oligodendrocytes of the adult brain, being considered
one of the main determinants of oligodendroglial
differentiation (Stolt et al., 2002). Although a high
number of astrocytomas express Sox10 (Bannykh et al.,
2006), such expression occurs at lower levels. In
connection with these reports, our findings demonstrated
Sox9 immunostaining in a large number of tumor cells,
but only a few cells expressed Sox10 immunoreactivity.
This observation suggests that experimental CT-2A
tumors might contain at least two chemically, and
perhaps functionally, distinct cell subpopulations.
However, the fact that tumor cells may modify antigenic
expressions during cell cycle should be taken into
account. Interestingly, we observed that not every GFAP
positive tumor cell expressed Sox9. This finding
correlates with the fact that in adult rodent brain Sox9
immunoreactivity colocalizes only partially (40%) with
astrocytes (Pompolo and Harley, 2001). The observation
of intense nuclear staining for Sox9 in our experimental
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tumor cells coincides with the same observation in high
grade tumors in humans (Dong et al., 2004; Bannykh et
al., 2006; Kordes and Hagel, 2006). The results of this
study reinforce the connection between Sox gene
expression and astrocytic tumors.
Tumor angiogenesis was evaluated in the CT-2A
experimental model both histologically and by contrast
enhanced MRI with gadolinium. Imaging plays a major
role in current cancer detection and treatment.
Monitoring techniques such as in vivo MRI allow for
evaluation studies of the validity of the model employed,
providing quantitative aspects of tumor biology, such as
growth kinetics, vascularity, and cellularity. Standard
T1- and T2-weighted MRI identify brain tumors with
high sensitivity. As in humans, the use of contrast-
enhanced MRI in mice with brain tumors provided in
vivo anatomical information on the cerebral tumor as to
its precise localization and extent. Besides primary
information on the size and localization of the tumor,
MRI also provides information on secondary phenomena
such as mass effect, edema, hemorrhage, necrosis, and
signs of increased intracranial pressure at high spatial
resolution and with high tissue contrast (Koutcher et al.,
2002). 
Although MRI can be very helpful for identifying
pathologic abnormalities, it has limitations when
evaluating gliomas (Floeth and Stummer, 2005; Dyke et
al., 2007) and histologic confirmation is necessary to
establish an accurate diagnosis. Normally, higher-grade
tumors frequently show enhancement on MRI, but
enhancement does not always equate with histologic
tumor grade. The HR-MAS 1H NMR application is
actually extensively applied to human tissues because it
correlates more closely with histologic findings and
provides a powerful tool for assessing tumor presence
and extent (Balmaceda et al., 2006; Hollingworth et al.,
2006; Omuro et al., 2006). Metabolite levels measured
with HR-MAS 1H NMR can be consistently correlated
with tumor types and grades and the monitoring of
progression of pathology in human brain (Li et al., 2004;
Dyke et al., 2007). In our study, HR-MAS 1H NMR
spectroscopy revealed distinct differences in the
metabolic tissue profile in CT-2A tumors compared with
normal contralateral parenchyma. These changes, which
showed a close relationship with previous findings in
human GBM (Li et al., 2004; Oh et al., 2004; Balmaceda
et al., 2006; Dyke et al., 2007), included a predominant
signal at 3.2 ppm and 3.22 ppm, attributed to Cho-
containing compounds, associated with low intensity
peaks at 3.04 ppm, attributable to Cr derivatives. Human
rapidly growing neoplasms show the common feature of
an increased Cho/Cr ratio, a decreased NAA/Cr ratio,
and an increased Lac/ Cr level (Li et al., 2004; Dyke et
al., 2007). The high Cho-containing compounds/Cr ratio
found has been linked with synthesis of new cell
membranes and increased membrane turnover and
higher cellular density (Floeth and Stummer, 2005;
Tugnoli et al., 2005). Interestingly, it has also been
proved that human pathological samples with increased
Lac/Cr ratio exhibited characteristic features of necrosis
(Son et al., 2001). The presence of elevated Cho and
decreased Ace has been found to correlate with tumor
histologic findings and may be used in distinguishing
regions of possible cancer from normal and other
noncancerous tissue, including necrosis and astrogliosis
(Dowling et al., 2001). Higher levels of Lac have been
attributed to hypoxia and the grade of malignancy of the
tumor and are usually detected in GBM (Castillo et al.,
1996; Dyke et al., 2007). Elevated Lac levels in CT-2A
tumor probably imply greater glucose and glycogen
levels in this region. Low signal at 2.02 attributable to
NAA was observed in CT-2A tumors, suggesting that a
decrease in brain NAA concentrations correlates directly
with histopathological evidence of neuronal loss in CT-
2A tumor as previously reported (Cheng et al., 1997).
High signals at 3.63 ppm (Myo), 3.56 ppm (Gly) and
3.26-3.42 ppm (Tau) were observed in CT-2A tumors.
The elevation of Myo and Tau is related to the
hypothesis that Myo is a glial marker and that Tau is
synthesized from cysteine by astrocytes but not by
primary neurons (Brand et al., 1993). Both in vivo and in
vitro NMR spectroscopy studies demonstrated that Myo,
Gly, and Tau concentrations were correlated with cell
density in tumors. The quantification of tumor metabolic
changes with HR-MAS, in conjunction with subsequent
histopathology of the same tumor specimen, has the
potential to further our knowledge on the biochemistry
of CT-2A tumor heterogeneity during progression, and
ultimately to improve our accuracy in diagnosing,
characterizing, and evaluating tumor progression for
preclinical trials.
In summary, orthotopic tumors produced by the
injection of CT-2A cells in the CP of C57BL/6J mice
closely resemble human GBM tumors and may be a
good model for preclinical trials of novel anticancer
drugs for CNS malignancies.
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